Stem cell inhaler to ease COVID-19 lung symptoms being tested in Abu Dhabi

Inhaler
(Image credit: iStock)

Researchers in the United Arab Emirates said Monday that they have seen "promising" results in a stem cell treatment for COVID-19 symptoms they have tested on 73 patients. If everything "went well and it worked well," Dr. Fatima al-Kaabi, head of hematology and oncology at the UAE's Sheikh Khalifa Medical City, told CNBC, the treatment could be ready for market in "three months' time."

The "minimally invasive" treatment, developed at the Abu Dhabi Stem Cell Center, involves extracting blood from patients, isolating stem cells, activating them, and turning them into a fine mist that the patient would inhale through a nebulizer or similar device, al-Kaabi said. It has helped alleviate coughing and other pulmonary symptoms, and "we've been happy that our initial safety results are promising, that's why we're heading into the next phase, of effectiveness of this treatment."

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
To continue reading this article...
Continue reading this article and get limited website access each month.
Get unlimited website access, exclusive newsletters plus much more.
Cancel or pause at any time.
Already a subscriber to The Week?
Not sure which email you used for your subscription? Contact us
Peter Weber, The Week US

Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.